688197 Stock Overview
Engages in the research, development, and production of pharmaceutical drugs in China. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Shouyao Holdings (Beijing) Co., LTD. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥33.75 |
52 Week High | CN¥61.63 |
52 Week Low | CN¥26.81 |
Beta | 1.24 |
11 Month Change | -7.99% |
3 Month Change | -0.44% |
1 Year Change | -41.07% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 5.11% |
Recent News & Updates
Shareholder Returns
688197 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -3.0% | 1.0% | -0.9% |
1Y | -41.1% | -4.8% | 5.4% |
Return vs Industry: 688197 underperformed the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 688197 underperformed the CN Market which returned 6.1% over the past year.
Price Volatility
688197 volatility | |
---|---|
688197 Average Weekly Movement | 8.7% |
Pharmaceuticals Industry Average Movement | 7.2% |
Market Average Movement | 8.3% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688197 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688197's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 185 | Wenjun Li | www.shouyaoholding.com |
Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of pharmaceutical drugs in China. The company offers products for various indications, such as non-small cell lung cancer, lymphoma, hepatocellular carcinoma; pancreatic, breast, ovarian, and thyroid cancer; leukemia; and other diseases, such as diabetes.
Shouyao Holdings (Beijing) Co., LTD. Fundamentals Summary
688197 fundamental statistics | |
---|---|
Market cap | CN¥5.02b |
Earnings (TTM) | -CN¥209.50m |
Revenue (TTM) | CN¥4.03m |
1,246x
P/S Ratio-24.0x
P/E RatioIs 688197 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688197 income statement (TTM) | |
---|---|
Revenue | CN¥4.03m |
Cost of Revenue | CN¥111.31k |
Gross Profit | CN¥3.92m |
Other Expenses | CN¥213.42m |
Earnings | -CN¥209.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.41 |
Gross Margin | 97.24% |
Net Profit Margin | -5,199.60% |
Debt/Equity Ratio | 0% |
How did 688197 perform over the long term?
See historical performance and comparison